I honestly don't expect it to run any higher than ACAD. About 8.50
You guys are extremely bullish and I hope the news does run us up to 10+, but I gotta see it to believe it.
Explain why this won't follow the same path as ACAD guys.
and while atopic dermatitis is nasty, untreatable bacterial infections are nastier. I think we can see, based upon your example, that analysts would quickly change the price target per share on Trius from 11.5 to 23 when/if it clears the second phase 3 trial in a few days. stock will go to 14 in 24 hours. Tedizolid will become drug of choice in its class. I have not fully researched trius next in line drugs, but even this one hit wonder would be enough.